Published in Mol Oncol on December 14, 2012
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) (2014) 0.91
Venus Flytrap (Dionaea muscipula Solander ex Ellis) Contains Powerful Compounds that Prevent and Cure Cancer. Front Oncol (2013) 0.86
SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol (2013) 0.81
In vivo tracking of human neural progenitor cells in the rat brain using bioluminescence imaging. J Neurosci Methods (2014) 0.81
Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers. Cancer Prev Res (Phila) (2015) 0.80
Imbalance of the antioxidative system by plumbagin and Plumbago indica L. extract induces hepatotoxicity in mice. J Intercult Ethnopharmacol (2016) 0.78
Plumbagin exhibits an anti-proliferative effect in human osteosarcoma cells by downregulating FHL2 and interfering with Wnt/β-catenin signalling. Oncol Lett (2016) 0.75
Plant-derived anticancer agents: a promising treatment for bone metastasis. Bonekey Rep (2014) 0.75
Population structure and genetic diversity of the perennial medicinal shrub Plumbago. AoB Plants (2015) 0.75
Tissue-specific conditional PKCε knockout mice: a model to precisely reveal PKCε functional role in initiation, promotion and progression of cancer. Oncotarget (2016) 0.75
Toxicogenomics of Phenylhydrazine Induced Hematotoxicity and its Attenuation by Plumbagin from Plumbago zeylanica. Pharmacogn Mag (2015) 0.75
Plumbagin-loaded aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol nanoparticles for prostate cancer therapy. Medicine (Baltimore) (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Tumor metastasis: mechanistic insights and clinical challenges. Nat Med (2006) 11.06
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol (2000) 7.94
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A (2000) 3.44
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol (2007) 2.06
Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions. Cell Cycle (2011) 1.74
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther (2006) 1.67
Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res (2007) 1.56
Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev (2010) 1.44
Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res (2005) 1.41
Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res (2008) 1.39
Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett (2007) 1.39
Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. J Neurochem (2009) 1.39
Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res (2002) 1.39
In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis (2003) 1.37
Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res (2007) 1.31
Animal models of bone metastasis. Cancer (2003) 1.29
Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene (2003) 1.29
Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm Res (2008) 1.24
Mechanisms of the development of androgen independence in prostate cancer. World J Urol (2005) 1.23
Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin. J Biol Chem (2009) 1.17
Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Lett (1998) 1.16
Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res (2008) 1.15
Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol Rep (2004) 1.09
Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. Mol Cancer Ther (2011) 1.02
Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res (2011) 0.98
Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther (2011) 0.97
Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? Am J Pathol (2010) 0.95
Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer (2012) 0.95
Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways. Int J Cancer (2012) 0.93
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia (2011) 0.92
Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice? Cancer (2008) 0.92
Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2. Br J Pharmacol (2012) 0.91
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiation-induced development of squamous cell carcinomas. Carcinogenesis (2011) 0.90
Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment. Curr Mol Med (2012) 0.89
Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers. Carcinogenesis (2012) 0.88
Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest (2011) 0.88
Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer. J Gene Med (2010) 0.82
Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J (2012) 0.82
Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model. Neoplasia (2012) 0.81
Prognostic impact of nm23-H1 and PCNA expression in pathologic stage I non-small cell lung cancer. J Surg Oncol (2011) 0.80
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 4.89
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol (2004) 2.39
Comparative validity of physical activity measures in older adults. Med Sci Sports Exerc (2011) 1.74
Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl (2008) 1.71
Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.70
Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res (2009) 1.57
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila) (2012) 1.57
cRGD-functionalized, DOX-conjugated, and ⁶⁴Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials (2011) 1.56
Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res (2007) 1.56
Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging (2008) 1.55
In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano (2012) 1.53
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res (2008) 1.52
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res (2010) 1.51
Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging (2011) 1.50
PET tracers based on Zirconium-89. Curr Radiopharm (2011) 1.48
Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today (2009) 1.47
Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem (2008) 1.46
PKCepsilon overexpression, irrespective of genetic background, sensitizes skin to UVR-induced development of squamous-cell carcinomas. J Invest Dermatol (2010) 1.46
microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med (2007) 1.46
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging (2007) 1.43
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev (2006) 1.41
Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. Am J Nucl Med Mol Imaging (2012) 1.41
Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res (2008) 1.39
Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res (2007) 1.38
18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med (2006) 1.37
Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One (2011) 1.36
In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano (2013) 1.34
Graphene: a versatile nanoplatform for biomedical applications. Nanoscale (2012) 1.32
Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res (2007) 1.31
Functional compensation in Hedgehog signaling during mouse prostate development. Dev Biol (2006) 1.29
Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation. Cancer Res (2009) 1.28
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol (2010) 1.27
Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials (2012) 1.27
Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med (2007) 1.26
Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials (2013) 1.26
A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila) (2010) 1.21
Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis. Prostate (2007) 1.17
Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med (2010) 1.16
Protein kinase C epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas. Cancer Res (2004) 1.15
Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res (2008) 1.14
Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Mol Pharm (2012) 1.14
ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. Am J Transl Res (2012) 1.14
Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol (2005) 1.14
Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol Cancer Ther (2006) 1.13
Protein kinase Cepsilon interacts with Stat3 and regulates its activation that is essential for the development of skin cancer. Mol Carcinog (2007) 1.12
Hexamodal imaging with porphyrin-phospholipid-coated upconversion nanoparticles. Adv Mater (2015) 1.11
Positron emission tomography imaging of prostate cancer. Amino Acids (2009) 1.11
Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging. Theranostics (2012) 1.11
Multimodality Imaging of Integrin α(v)β(3) Expression. Theranostics (2011) 1.10
Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol (2009) 1.10
Preparation and functionalization of graphene nanocomposites for biomedical applications. Nat Protoc (2013) 1.10
Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells. Cancer Chemother Pharmacol (2008) 1.10
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol (2014) 1.09
Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells. Carcinogenesis (2008) 1.09
Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med (2008) 1.09
Semiconductor quantum dots for in vivo imaging. J Nanosci Nanotechnol (2007) 1.07
Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation (2008) 1.07
In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene. Biomaterials (2012) 1.07
Non-invasive cell tracking in cancer and cancer therapy. Curr Top Med Chem (2010) 1.07
Chelator-free synthesis of a dual-modality PET/MRI agent. Angew Chem Int Ed Engl (2013) 1.05
Expression of p53 enhances selenite-induced superoxide production and apoptosis in human prostate cancer cells. Cancer Res (2006) 1.05
HaloTag: a novel reporter gene for positron emission tomography. Am J Transl Res (2011) 1.04
Extracellular redox state regulates features associated with prostate cancer cell invasion. Cancer Res (2008) 1.03
Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov (2007) 1.03
PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging (2013) 1.03
Immuno-PET of tissue factor in pancreatic cancer. J Nucl Med (2012) 1.02
In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.02
Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol Cancer Ther (2008) 1.01
Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody. Mol Pharm (2012) 1.01
The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Neurol Res (2008) 1.01
Cancer-targeted optical imaging with fluorescent zinc oxide nanowires. Nano Lett (2011) 1.00
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1. Oncogene (2003) 1.00
Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res (2008) 1.00
Intrinsically radiolabeled nanoparticles: an emerging paradigm. Small (2014) 0.99
Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression. Free Radic Biol Med (2010) 0.99
Iron oxide decorated MoS2 nanosheets with double PEGylation for chelator-free radiolabeling and multimodal imaging guided photothermal therapy. ACS Nano (2015) 0.99